Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Inclusion criteria: * Type 2 diabetes mellitus, treated with Lantus±SU; ≥5-year after diagnosis * Aged 20-75 years * Hemoglobin A1C ≥7.0%-≤10.0% * Fasting plasma glucose ≤180 mg/dL at screening * Stable treatment (±20%) with Lantus for 3 months or more prior to screening. * Sulfonylurea dose stable for 3 months or more prior to screening Exclusion criteria: * Type 1 diabetes mellitus * Pregnancy or lactation * Hypersensitivity to Lixisenatide * Severely uncontrolled glycemic situation * History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery or inflammatory bowel disease * History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening * History within the previous 6 months of myocardial infarction, stroke or heart failure requiring hospitalization or drug or alcohol abuse * Uncontrolled/inadequately controlled hypertension at the time of screening, with a resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>95 mmHg * Amylase and/or lipase \>3 times or aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP) \>2 times the upper limit of the normal laboratory range * End-stage renal disease and/or dialysis and clinically relevant history of gastrointestinal disease The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial